Carlos Manalich, MD
Internal Medicine · Greenwood, SCNPI 1003871997
Payments from drug & device makers
Across 208 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$583
- Novo Nordisk$468
- AstraZeneca$267
- Lilly USA, LLC$224
- Johnson & Johnson$198
- Sumitomo Pharma America, Inc.$180
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,55099%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 35 | $583 |
| Novo Nordisk | 33 | $468 |
| AstraZeneca | 10 | $267 |
| Lilly USA, LLC | 14 | $224 |
| Johnson & Johnson | 8 | $198 |
| Sumitomo Pharma America, Inc. | 10 | $180 |
| Sanofi-aventis U.S. LLC | 11 | $176 |
| Pfizer | 11 | $167 |
| Novartis | 10 | $166 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $140 |
| AbbVie(2 entities) | 8 | $122 |
| Xeris Pharmaceuticals, Inc. | 5 | $90 |
| Edwards Lifesciences | 3 | $85 |
| Amarin Pharma, Inc. | 5 | $78 |
| Dexcom, Inc. | 4 | $73 |
| GSK | 4 | $73 |
| Astellas Pharma US Inc | 4 | $72 |
| Bayer | 3 | $62 |
| Boehringer Ingelheim | 3 | $52 |
| Exact Sciences | 3 | $47 |
| Abiomed | 2 | $39 |
| Dynavax Technologies Corporation | 1 | $31 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Cepheid | 1 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| EKOS Corporation | 1 | $19 |
| Merck | 1 | $16 |
| Corcept Therapeutics | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,583 in reported general payments places this provider in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 154 | $147,188 |
| XifaxanRifaximin | 32 | $106,859 |
| EliquisApixaban | 94 | $87,183 |
| TrulicityDulaglutide | 37 | $53,400 |
| JardianceEmpagliflozin | 38 | $38,514 |
| RybelsusSemaglutide | 20 | $25,491 |
| Repatha SureclickEvolocumab | 29 | $25,222 |
| MounjaroTirzepatide | 27 | $24,150 |
| XareltoRivaroxaban | 24 | $22,741 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $22,312 |
| JanumetSitagliptin Phos/Metformin Hcl | 21 | $17,927 |
| LinzessLinaclotide | 28 | $17,316 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $15,653 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $14,799 |
| Xtampza ErOxycodone Myristate | 22 | $13,199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $468 | $172,679174 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $140 | $106,85932 claims |
| PfizerEliquis | $167 | $87,18394 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $224 | $77,55164 claims |
| MerckJanumet, Januvia, Janumet Xr | $16 | $41,68663 claims |
| Boehringer IngelheimJardiance | $52 | $38,51438 claims |
| AbbVieLinzess, Namzaric | $122 | $23,98840 claims |
| Johnson & JohnsonXarelto | $198 | $22,74124 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $176 | $14,79917 claims |
| Astellas Pharma US IncMyrbetriq | $72 | $11,74219 claims |
| AstraZenecaFarxiga | $267 | $9,59315 claims |
| GSKBreo Ellipta | $73 | $7,26820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Greenwood
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
- Carl SofleyAnderson$673K
- Carl MitchellColumbia$564K
- Jerry BackNorth Charleston$322K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.